Bioneutral Group holds scientific and business discussions with major health care companies

BioNeutral Group, Inc. (“BioNeutral”) (OTCBB:BONU), a specialty chemical technology based Life Science Company, announced discussions with four of the world’s largest health care companies. The discussions included both scientific and business representatives all interested in BioNeutral's game changing technology - "Sporicidal performance on surfaces and skin.” Game changing technology is an infrequent occurrence. However, it is easy to identify and differentiate from the run of the mill or obsolete technology and thus generates intense interest. BioNeutral is in a unique position in that it has not solicited contacts with major players in the antimicrobial and health care arena; instead these well known companies have been contacting BioNeutral to develop partnering relationships.

Any antimicrobial which is not sporicidal may be a carrier for the dangerous and difficult to kill organisms which may then be transported from person to person (this includes all known alcohol, silver or quat based formulations). For example, Clostridium Difficile spores are associated with hospital acquired infections which results in diverted heath care provider’s efforts, millions of dollars in extra expenses and hundreds of thousands of unnecessary deaths annually in the US alone. The best high powered currently used hospital disinfectants based upon quaternary ammonium compounds, silver based disinfectants or alcohol washes are totally ineffective at eradicating Clostridium Difficile (C-diff) spores, resulting in a serious unmet need in the health care arena. BioNeutral’s Ygiene™ is the clear solution for this serious problem.

Dr. Andy Kielbania, Chief Scientist at BioNeutral Group stated, "Results of in-house testing conducted this past week demonstrated a 30 second kill time for the most difficult to kill spores with a mild formulation that is gentle to skin, surfaces and fabric. These are the best results we have produced thus far.”

“When these results are confirmed by independent testing,” said one of the health care executives, “It represents a game changer which will determine control of a worldwide antimicrobial health care market.”

BioNeutral Group Inc. CEO, Stephen J. Browand, stated, "If game changing technology were presently out there, we would not be inundated with calls from the major players in the healthcare field. Killing low level microorganisms with old, me too technology (alcohol, silver, quats or bleach) has been available for quite some time. Rapidily eliminating dangerous spores such as Clostridium Difficile (C-diff) with our new mild Ygiene™ formulation which can be exposed to skin is considered the holy grail of antimicrobial performance. Independent lab testing confirming last week’s R&D breakthrough should take approximately three weeks".

BioNeutral Group Inc. has confirmed independent test results which indisputably show the Company’s Ygiene™ formulations outperform virtually all antimicrobials available when it comes to difficult to kill, dangerous organisms including black mold. Dissimilar to silver, bleach and quat based older technology; BioNeutral’s Ygiene™ is non corrosive, non-staining, non flammable and completely sporicidal.

Comments

  1. roberta roberta United States says:

    I just had my apartment tested for mold and I have high levels of black mold, could this be the reason I have been hospitalized 3 times in the past year and most recently diagnosed with c-diff - is there a connection?

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
You might also like... ×
Reassuring news about the protection that SARS-CoV-2 vaccines offer